(NASDAQ: FBRX) Forte Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.42%.
Forte Biosciences's earnings in 2026 is -$75,855,000.On average, 7 Wall Street analysts forecast FBRX's earnings for 2026 to be -$85,767,333, with the lowest FBRX earnings forecast at -$93,723,354, and the highest FBRX earnings forecast at -$69,238,880. On average, 7 Wall Street analysts forecast FBRX's earnings for 2027 to be -$88,816,629, with the lowest FBRX earnings forecast at -$118,609,212, and the highest FBRX earnings forecast at -$62,142,970.
In 2028, FBRX is forecast to generate -$91,351,907 in earnings, with the lowest earnings forecast at -$114,996,749 and the highest earnings forecast at -$56,122,198.